High-throughput screening automation and BLI technology implementation at Sanofi for engineering next-gen multi-specific antibody therapeutics
Wednesday, September 17, at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT
Join Anja Wille as she explores how Sanofi has transformed antibody therapeutic development through advanced automation and screening technologies. Discover an end-to-end automated platform to engineer next-generation multi-specific antibody therapeutics at unprecedented scale.
She will cover the shift from traditional workflows to high-throughput platforms handling 10,000+ variants, and how the integration of multiple robotic platforms streamlines DNA handling, protein expression, and analysis.
This SelectScience® webinar will highlight how this integrated approach has successfully executed over 30 campaigns, significantly increasing the probability of success while generating valuable data for machine learning and AI applications.
Plus, you will learn about the use of biolayer interferometry (BLI) technology for rapid quantitation and off-rate screening and see real-world success stories, including Fab affinity maturation campaigns.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers
Who should attend?
- Biopharmaceutical R&D scientists - Particularly those working in antibody engineering, protein science, and therapeutic development
- Laboratory automation specialists - Professionals interested in high-throughput screening technologies and workflow optimization
- Assay development scientists - Those working with or interested in BLI technology applications for quantitation and binding kinetics
- Bioprocess engineers - Professionals involved in scaling antibody production and quality assessment
- Research directors and managers - Decision-makers evaluating technologies to enhance R&D productivity and efficiency
- Academic researchers - Scientists in immunology, protein engineering, and biotherapeutics development seeking insights into industrial-scale approaches
Featured products
Request Quote for All Products
Octet® RH96 BLI System
Sartorius GroupUnrivaled performance with 2 minutes to quantitate 96 samples or 15 minutes to run 384 binding kinetics.
What will this webinar cover?
Key learning objectives:
- Understand how an integrated automated platform transforms traditional antibody development into a high-throughput process capable of handling 10,000+ variants simultaneously
- Learn about the implementation and benefits of BLI technology for rapid quantitation and off-rate screening, including practical insights from real campaign data
- Discover how automation across the entire value chain (from DNA handling to protein analysis) increases the probability of success and generates valuable data for AI applications
Join the webinar to get answers to these questions:
- How does an integrated automated platform enable high-throughput antibody development with 10,000+ variants?
- In what ways does automation streamline DNA handling, protein expression, and analysis across the value chain?
- How is biolayer interferometry (BLI) used for rapid quantitation and off-rate screening in antibody campaigns?
- How does this end-to-end platform increase campaign success rates and support AI and machine learning?
- What real-world results have been achieved, including Fab affinity maturation and multi-specific antibody engineering?